Table of Contents Table of Contents
Previous Page  56 / 66 Next Page
Information
Show Menu
Previous Page 56 / 66 Next Page
Page Background

Balar AV, Lancet. 2017 Jan;389(10064):67–76.

Pembrolizumab 1st line, cisplatin ineligible

1 … 51 52 53 54 55 56 57 58 59 60 61 62 … 66  FlippingBook